Srihari Gopal

Global Program Head

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Srihari Gopal serves as the Global Program Head at Regeneron in the United States. His research areas primarily focus on pharmacokinetic characteristics and efficacy of long-acting injectable antipsychotics for schizophrenia, as well as genome-wide association studies related to suicide death and suicidal behavior. Recent contributions include analyses on the effectiveness of various formulations of paliperidone and patients' preferences for long-acting injectable versus oral antipsychotics.

Articles (11)

Year:

2025

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Collaborators (9)

Nolan Kamitaki

Broad Institute

UNITED STATES

View details

Anna Docherty

UNITED STATES

View details

Aarno Palotie

University of Helsinki

FINLAND

View details

Stephen Saklad

Clinical Professor, Director of Psychiatric Pharmacy

University of Texas at Austin

UNITED STATES

View details

Maurizio Pompili

Sapienza University of Rome

ITALY

View details

John Powell

Emeritus Professor of Human Genetics

King's College London

UNITED KINGDOM

View details

Paul Tooney

AUSTRALIA

View details

Marcus Sokolowski

Healthcare Provision, Stockholm County

SWEDEN

View details

David Morris

King’s College London

UNITED KINGDOM

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Srihari Gopal

Research Interests

Explore related searches

Contact this professor

About

Articles (11)

Correction: Pharmacokinetic Characteristics of Long‑Acting Injectable Antipsychotics for Schizophrenia: An Overview

Genome-wide association study meta-analysis of suicide death and suicidal behavior

Efficacy and Safety of Paliperidone Palmitate 6-Month versus Paliperidone Palmitate 3-Month Long-Acting Injectable in European Patients with Schizophrenia: A Post Hoc Analysis of a Global Phase-3 Double-Blind Randomized Non-Inferiority Study

The Effect of Longer Dosing Intervals for Long-Acting Injectable Antipsychotics on Outcomes in Schizophrenia

Comparing Relapse Rates in Real-World Patients with Schizophrenia Who Were Adequately versus Not Adequately Treated with Paliperidone Palmitate Once-Monthly Injections Before Transitioning to Once-Every-3-Months Injections

Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview

Defining “Adequately Treated”: A Post Hoc Analysis Examining Characteristics of Patients with Schizophrenia Successfully Transitioned from Once-Monthly Paliperidone Palmitate to Once-Every-3-Months Paliperidone Palmitate

Complement genes contribute sex-biased vulnerability in diverse disorders

Effect of Paliperidone Palmitate 3-Month Formulation on Goal Attainment and Disability After 52 Weeks’ Treatment in Patients with Clinically Stable Schizophrenia

<p>Patients’ Preference for Long-Acting Injectable versus Oral Antipsychotics in Schizophrenia: Results from the Patient-Reported Medication Preference Questionnaire</p>

<p>Comparison of Relapse Prevention with 3 Different Paliperidone Formulations in Patients with Schizophrenia Continuing versus Discontinuing Active Antipsychotic Treatment: A Post-Hoc Analysis of 3 Similarly Designed Randomized Studies</p>

Collaborators (9)

Nolan Kamitaki

Anna Docherty

Aarno Palotie

Stephen Saklad

Maurizio Pompili

John Powell

Paul Tooney

Marcus Sokolowski

David Morris

Make your next move.